Almotriptan Malate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317170

CAS#: 181183-52-8(Almotriptan Malate)

Description: Almotriptan Malate is a triptan drug discovered and developed by Almirall for the treatment of heavy migraine headache. Almotriptan is a Serotonin-1b and Serotonin-1d Receptor Agonist. Binding of the drug to the receptor leads to vasoconstriction of the cranial blood vessels and thus affects the redistribution of cranial blood flow. Almotriptan significantly increases cerebral blood flow and reduces blood flow through extracerebral cranial vessels. Even though it affects cranial blood vessels a single dose of almotriptan (12.5 mg) has no clinically significant effect on blood pressure or heart rate in both young and elderly healthy volunteers.

Chemical Structure

Almotriptan Malate
CAS# 181183-52-8(Almotriptan Malate)

Theoretical Analysis

MedKoo Cat#: 317170
Name: Almotriptan Malate
CAS#: 181183-52-8(Almotriptan Malate)
Chemical Formula: C17H25N3O2S
Exact Mass: 335.16675
Molecular Weight: 335.46
Elemental Analysis: C, 60.87; H, 7.51; N, 12.53; O, 9.54; S, 9.56

Price and Availability

Size Price Availability Quantity
25.0mg USD 350.0 2 Weeks
100.0mg USD 650.0 2 Weeks
Bulk inquiry

Related CAS #: 181183-52-8(Almotriptan Malate)   154323-57-6 (free base)  

Synonym: Almogran; Almotrex; Amignul; Axert; Almotriptan Malate.

IUPAC/Chemical Name: N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethan-1-amine 2-hydroxysuccinate


InChi Code: InChI=1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 335.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Abbas Z, Marihal S. Gellan gum-based mucoadhesive microspheres of almotriptan for nasal administration: Formulation optimization using factorial design, characterization, and in vitro evaluation. J Pharm Bioallied Sci. 2014 Oct;6(4):267-77. doi: 10.4103/0975-7406.142959. PubMed PMID: 25400410; PubMed Central PMCID: PMC4231387.

2: Orlandini S, Pasquini B, Stocchero M, Pinzauti S, Furlanetto S. An integrated quality by design and mixture-process variable approach in the development of a capillary electrophoresis method for the analysis of almotriptan and its impurities. J Chromatogr A. 2014 Apr 25;1339:200-9. doi: 10.1016/j.chroma.2014.02.088. Epub 2014 Mar 12. PubMed PMID: 24656544.

3: Castagno E, Lupica M, Viola S, Savino F, Miniero R. Creatin-kinase elevation after accidental ingestion of almotriptan in an 18-month-old girl. Minerva Pediatr. 2014 Feb;66(1):95-7. PubMed PMID: 24608586.

4: Lavudu P, Rani AP, Divya C, Sekharan CB. High performance liquid chromatographic analysis of almotriptan malate in bulk and tablets. Adv Pharm Bull. 2013;3(1):183-8. doi: 10.5681/apb.2013.030. Epub 2013 Feb 7. PubMed PMID: 24312833; PubMed Central PMCID: PMC3846065.

5: Nirogi R, Ajjala DR, Kandikere V, Aleti R, Pantangi HR, Srikakolapu SR, Benade V, Bhyrapuneni G, Vurimindi H. LC-MS/MS method for the quantification of almotriptan in dialysates: application to rat brain and blood microdialysis study. J Pharm Biomed Anal. 2013 Jul-Aug;81-82:160-7. doi: 10.1016/j.jpba.2013.04.008. Epub 2013 Apr 16. PubMed PMID: 23666253.

6: Negro A, Lionetto L, D'Alonzo L, Casolla B, Marsibilio F, Vignaroli G, Simmaco M, Martelletti P. Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2013 May;9(5):637-44. doi: 10.1517/17425255.2013.783012. Epub 2013 Apr 9. PubMed PMID: 23570251.

7: Ravikumar K, Chandu BR, Challa BR, Chandrasekhar KB. Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study. Sci Pharm. 2012 Jun;80(2):367-78. doi: 10.3797/scipharm.1112-01. Epub 2012 Feb 27. PubMed PMID: 22896823; PubMed Central PMCID: PMC3383208.

8: Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Fierro B, Brighina F. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain. 2012 Jul;13(5):401-6. doi: 10.1007/s10194-012-0455-4. Epub 2012 May 17. PubMed PMID: 22592864; PubMed Central PMCID: PMC3381066.

9: Oberhardt F, Fox AW. Oral sumatriptan and almotriptan--delimiting the MAOI effect. Headache. 2012 May;52(5):765-72. doi: 10.1111/j.1526-4610.2012.02113.x. Epub 2012 Mar 21. PubMed PMID: 22435741.

10: Nageswara Rao R, Guruprasad K, Gangu Naidu Ch, Raju B, Srinivas R. LC-ESI-MS/MS determination of in vivo metabolites of almotriptan in rat plasma, urine and feces: application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 1;891-892:44-51. doi: 10.1016/j.jchromb.2012.02.017. Epub 2012 Feb 20. PubMed PMID: 22406349.

Additional Information

181183-52-8 (Almotriptan free base)
154323-57-6 (Almotriptan HCl)